









Markets
/
Stocks
/
nasdaq-kymr
/

Kymera Therapeutics Inc

KYMR

49.130USD

-2.030-3.97%

Close 09/19, 16:00（ET）Quotes delayed by 15 min

3.47BMarket Cap

LossP/E TTM



Kymera Therapeutics Inc

49.130

-2.030-3.97%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated: 2025-09-19

Key Insights

The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite a very weak market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking

30 / 506

Overall Ranking

110 / 4720

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 21 analysts

Buy

Current Rating

63.053

Target Price

+23.25%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

Kymera Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural protein degradation system. The Company's targeted protein degradation (TPD) platform, which it refers to as Pegasus, allows it to discover highly selective small molecule protein degraders with activity against disease-causing proteins throughout the body. It utilized its Pegasus platform to design novel protein degraders focused in the areas of immunology-inflammation and oncology, and it continues to apply its platform’s capabilities to additional therapeutic areas. Its clinical stage programs are IRAK4, STAT3, and MDM2, which each address high impact targets within biologically proven pathways, providing the opportunity to treat a range of immuno-inflammatory diseases, hematologic malignancies, and/or solid tumors.

Growing

The company is in a growing phase, with the latest annual income totaling USD 47.07M.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 44.60.

Undervalued

The company’s latest PE is -14.06, at a low 3-year percentile range.

Institutional Buying

The latest institutional holdings are 76.16M shares, increasing 0.54% quarter-over-quarter.

Held by PRFDX

Star Investor PRFDX holds 6.80M shares of this stock.

Financial Health

Currency: USD Updated: 2025-09-19

The company's current financial score is 6.86, which is lower than the Biotechnology & Medical Research industry's average of 6.93. Its financial status is robust, and its operating efficiency is low. Its latest quarterly revenue reached 11.48M, representing a year-over-year decrease of 55.26%, while its net profit experienced a year-over-year decrease of 82.15%.

Score

Industry at a Glance

Previous score

6.86

Change



Financials

8.50

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

7.48

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

2.87

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

8.20

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.25

Key Metrics

Free cash flow

No Data

Company Valuation

Currency: USD Updated: 2025-09-19

The company’s current valuation score is 2.80, which is lower than the Biotechnology & Medical Research industry's average of 3.06. Its current P/E ratio is -14.64, which is -33.87% below the recent high of -9.68 and 6.47% above the recent low of -13.70.

Score

Industry at a Glance

Previous score

2.80

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 30/506

No Data

Earnings Forecast

Currency: USD Updated: 2025-09-19

The company’s current earnings forecast score is 9.00, which is higher than the Biotechnology & Medical Research industry's average of 8.03. The average price target for Kymera Therapeutics Inc is 60.00, with a high of 88.00 and a low of 53.00.

Score

Industry at a Glance

Previous score

9.00

Change

Support & Resistance

No Data

Analyst Rating

Based on 21 analysts

Buy

Current Rating

63.053

Target Price

+23.25%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

554

Total

Median

Average

Company name

Ratings

Analysts

Kymera Therapeutics Inc

KYMR

CRISPR Therapeutics AG

CRSP

Intellia Therapeutics Inc

NTLA

Exact Sciences Corp

EXAS

Ionis Pharmaceuticals Inc

IONS

IQVIA Holdings Inc

IQV

...

111

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-09-19

The company’s current price momentum score is 9.30, which is higher than the Biotechnology & Medical Research industry's average of 6.58. Sideways: Currently, the stock price is trading between the resistance level at 55.36 and the support level at 43.40, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

9.30

Change

-0.3

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(2)

Neutral(2)

Buy(3)

Indicators

Value

Direction

MACD(12,26,9)

1.489

Buy

RSI(14)

63.077

Neutral

STOCH(KDJ)(9,3,3)

78.678

Neutral

ATR(14)

2.267

High Vlolatility

CCI(14)

104.662

Buy

Williams %R

22.324

Buy

TRIX(12,20)

0.518

Sell

StochRSI(14)

0.000

Sell

Moving Average

Sell(0)

Neutral(0)

Buy(6)

Indicators

Value

Direction

MA5

48.894

Buy

MA10

46.788

Buy

MA20

44.629

Buy

MA50

43.912

Buy

MA100

41.420

Buy

MA200

38.630

Buy

Institutional Confidence

Currency: USD Updated: 2025-09-19

The company’s current institutional recognition score is 10.00, which is higher than the Biotechnology & Medical Research industry's average of 5.96. The latest institutional shareholding proportion is 108.56%, representing a quarter-over-quarter increase of 1.69%. The largest institutional shareholder is PRFDX, holding a total of 6.80M shares, representing 9.51% of shares outstanding, with 9.63% decrease in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

T. Rowe Price Associates, Inc.

Star Investors

6.65M

-2.49%

Baker Bros. Advisors LP

6.65M

+10.93%

Avoro Capital Advisors LLC

6.46M

+25.44%

The Vanguard Group, Inc.

Star Investors

5.22M

+7.05%

BVF Partners L.P.

5.48M

+6.14%

Fidelity Management & Research Company LLC

4.41M

-8.72%

Wellington Management Company, LLP

6.00M

+12.99%

Atlas Venture

4.90M

BlackRock Institutional Trust Company, N.A.

3.63M

-2.07%

Invus Public Equities Advisors, LLC

3.24M

+9.11%

Risk Assessment

Currency: USD Updated: 2025-09-19

The company’s current risk assessment score is 3.17, which is lower than the Biotechnology & Medical Research industry's average of 3.33. The company's beta value is 2.23. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.